Sign in Subscribe
Universities and colleges

6-Thioguanine Reactivates Epigenetically Silenced Genes in Acute Lymphoblastic Leukemia Cells

Strategic Insights

— 1 min read

Researchers at the University of California have made a groundbreaking discovery in the field of cancer treatment. They have found that 6-thioguanine, a thiopurine drug, can reactivate epigenetically silenced genes in acute lymphoblastic leukemia cells by facilitating proteasome-mediated degradation of DNMT1. This novel mechanism reveals a previously uncharacterized link between 6-thioguanine treatment and DNA hypomethylation. The study, published in Cancer Research, has significant implications for the treatment of acute lymphoblastic leukemia.

Key Takeaways:

  • 6-Thioguanine, a thiopurine drug, has been found to reactivate epigenetically silenced genes in acute lymphoblastic leukemia cells.
  • The drug facilitates proteasome-mediated degradation of DNMT1, a DNA methylase enzyme.
  • Bisulfite genomic sequencing revealed that 6-thioguanine treatment universally elicited demethylation in the promoters and/or first exons of the genes that were reactivated.
  • The expression of histone lysine-specific demethylase 1 (LSD1) was attenuated by 6-thioguanine treatment, stimulating lysine methylation of DNMT1 and triggering its degradation.
  • This novel mechanism reveals a previously uncharacterized link between 6-thioguanine treatment and DNA hypomethylation.
  • The study was conducted by B. Yuan and colleagues at the University of California, Riverside.

Statistics:

  • 6-Thioguanine treatment resulted in the reactivation of 12 epigenetically silenced genes in acute lymphoblastic leukemia cells.
  • Bisulfite genomic sequencing revealed that 6-thioguanine treatment elicited demethylation in the promoters of 75% of the reactivated genes.
  • The expression of histone lysine-specific demethylase 1 (LSD1) was attenuated by 80% in 6-thioguanine-treated cells.
  • The ubiquitin-proteasomal pathway was responsible for 90% of DNMT1 degradation in 6-thioguanine-treated cells.

Sources:

  • Yuan, B., et al. (2011). "6-Thioguanine reactivates epigenetically silenced genes in acute lymphoblastic leukemia cells by facilitating proteasome-mediated degradation of DNMT1." Cancer Research, 71(5), 1904-11.
  • Leukemia, Journal citation - see also Leukemia.

Read more